Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children

Eur J Pediatr. 1997 Feb;156(2):90-3. doi: 10.1007/s004310050561.

Abstract

The effectiveness of systemic corticosteroids in erythema multiforme major (EMM) is controversial. We therefore evaluated the efficacy of corticosteroids in the treatment of EMM in a prospective study of 16 children with EMM admitted to our department within 3 days from the onset of rash. Ten patients (group A) received bolus infusions of methylprednisolone (4 mg/kg/day) while six had only supportive treatment (group B). The early use of corticosteroids compared to supportive treatment resulted in: (1) significant reduction of the period of fever (4.0 +/- 1.9 vs 9.5 +/- 4.2 days P = 0.01); (2) reduction of the period of acute eruption (7.0 +/- 3.3 versus 9.8 +/- 3.0 days P = 0.08); and (3) milder signs of prostration. Complications were minimal in both groups.

Conclusion: The early and short course of corticosteroids favourably influences the course of erythema multiforme major in children.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Methylprednisolone / therapeutic use*
  • Prospective Studies
  • Stevens-Johnson Syndrome / drug therapy*
  • Stevens-Johnson Syndrome / physiopathology

Substances

  • Glucocorticoids
  • Methylprednisolone